Dashboard
1
High Management Efficiency with a high ROCE of 13.16%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 53.79
3
Positive results in Jun 25
4
With ROCE of 1.54%, it has a very attractive valuation with a 1.20 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
JPY 218,286 Million (Small Cap)
47.00
NA
0.01%
0.26
1.95%
1.66
Revenue and Profits:
Net Sales:
61,395 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1,231 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-13.66%
0%
-13.66%
6 Months
5.91%
0%
5.91%
1 Year
29.41%
0%
29.41%
2 Years
28.16%
0%
28.16%
3 Years
18.92%
0%
18.92%
4 Years
17.61%
0%
17.61%
5 Years
16.28%
0%
16.28%
H.U. Group Holdings, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.19%
EBIT Growth (5y)
-23.29%
EBIT to Interest (avg)
53.79
Debt to EBITDA (avg)
0.99
Net Debt to Equity (avg)
0.25
Sales to Capital Employed (avg)
1.15
Tax Ratio
15.02%
Dividend Payout Ratio
257.23%
Pledged Shares
0
Institutional Holding
0.12%
ROCE (avg)
13.16%
ROE (avg)
10.96%
Valuation key factors
Factor
Value
P/E Ratio
47
Industry P/E
Price to Book Value
1.25
EV to EBIT
78.04
EV to EBITDA
8.81
EV to Capital Employed
1.20
EV to Sales
0.85
PEG Ratio
0.31
Dividend Yield
0.02%
ROCE (Latest)
1.54%
ROE (Latest)
2.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Jun 2017
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.12%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
61,395.00
60,978.00
0.68%
Operating Profit (PBDIT) excl Other Income
6,308.00
5,326.00
18.44%
Interest
168.00
178.00
-5.62%
Exceptional Items
-246.00
-886.00
72.23%
Consolidate Net Profit
-1,231.00
-63.00
-1,853.97%
Operating Profit Margin (Excl OI)
14.20%
-0.30%
1.45%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 0.68% vs -1.74% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -1,853.97% vs -101.74% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
243,025.00
236,950.00
2.56%
Operating Profit (PBDIT) excl Other Income
23,092.00
16,826.00
37.24%
Interest
591.00
399.00
48.12%
Exceptional Items
-360.00
-273.00
-31.87%
Consolidate Net Profit
2,731.00
-7,553.00
136.16%
Operating Profit Margin (Excl OI)
9.70%
-17.10%
2.68%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 2.56% vs -9.18% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 136.16% vs -148.18% in Mar 2024
About H.U. Group Holdings, Inc. 
H.U. Group Holdings, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






